Skip to content

Discovery Value Fund

Follow

13F filer, CIK 1750451, SINGAPORE, Singapore

Discovery Value Fund reported $51,586,083 across 3 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001750451-25-000006

Period
2025-06-30
Reported value
$51.6M
Holdings
3
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
DASHreduced-111,728-$27.5M
NVDAreduced-105,231-$16.6M
NTLAreduced-332,860-$3.12M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001750451-25-000006, largest first. % of portfolio is the value over $51,586,083, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NVDANVIDIA CORPORATIONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 90,257 shares; 2024Q4: 339,545 shares; 2025Q1: 329,665 shares; 2025Q2: 224,434 shares 224,434$35.5M68.74%-105,231Timeline
DASHDOORDASH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,072,706 shares; 2024Q4: 635,908 shares; 2025Q1: 168,450 shares; 2025Q2: 56,722 shares 56,722$14M27.11%-111,728Timeline
NTLAINTELLIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 561,561 shares; 2024Q4: 561,561 shares; 2025Q1: 561,561 shares; 2025Q2: 228,701 shares 228,701$2.15M4.16%-332,860Timeline

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001750451-25-000006 base2025-08-12acceptance time not in the bulk data set